|
NCI9782
|
A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors |
Open |
|
UW16107
|
A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors |
Open |
|
UW17055
|
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
|
Open |
|
UW15054
|
A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies |
Open |
|
AGCT1531
|
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
Open |
|
UW13043
|
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014 |
Open |
|
UW16116
|
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers |
Open |
|
GOG3015
|
A Phase III, Multicenter, Randomized Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Open |
|
ARST1431
|
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) |
Open |
|
NRGGY009
|
A Randomized Phase II/III Study of Pegylated Liposomal Doxorubicin (PLD) and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs. Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW17152
|
An Open-Label Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
|
Open |
|
UW16137
|
An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas |
Open |
|
UW14030
|
Epidural Analgesia as Part of an Enhanced Recovery Pathway in Gynecologic Surgery
|
Open |
|
UW15106
|
Genomic analysis of long-term survivors with metastatic cancer |
Open |
|
ALTE15N2
|
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study |
Open |
|
UW15000
|
Mindfulness-Based Interventions in Patients Treated for Gynecologic Cancer - Impact on Patient Reported Outcomes and Immunologic Correlates |
Open |
|
UW18018
|
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
UW17017
|
PSMA Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging in Gynecological Cancers |
Open |
|
UW17077
|
Patient Attitudes Toward the Use of Vibrating Vaginal Dilators in Women Who Have Received Radiation for Gynecologic Malignancies
|
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
ADVL1622
|
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors |
Open |
|
UW17010
|
Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer |
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
UW17121
|
Prevalence of Abuse in the Sexual Health Clinic
|
Open |
|
UW16009
|
Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
UW Carbone
